Literature DB >> 12411289

Von Willebrand disease type 1: a diagnosis in search of a disease.

J Evan Sadler1.   

Abstract

Von Willebrand disease (VWD) type 1 is reported to be common but frequently is difficult to diagnose. Many people have nonspecific mild bleeding symptoms, von Willebrand factor (VWF) levels display low heritability, and low VWF levels (15% to 50% of normal) are weak risk factors for bleeding. Therefore, bleeding and low VWF levels often associate by chance. Even with stringent diagnostic criteria based on a triad of bleeding symptoms, a low VWF level, and a positive family history, the prevalence of "false-positive" VWD type 1 is comparable to the published prevalence of the disease. Consequently, many patients diagnosed with VWD type 1 do not have a specific hemorrhagic disease at all, which limits the utility of the diagnosis. This unfortunate reality is a consequence of trying to force patients into binary categories of "diseased" or "healthy" that are incompatible with the continuous biologic context in which VWF functions. The problem may be avoided by substituting an empirical epidemiologic approach like that applied to other modest risk factors for disease such as elevated cholesterol and high blood pressure. Such a risk management strategy could be generalized to include other hemorrhagic and thrombotic risk factors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411289     DOI: 10.1182/blood-2002-09-2892

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  Chitosan scaffold enhances growth factor release in wound healing in von Willebrand disease.

Authors:  Mercy Halleluyah Periayah; Ahmad Sukari Halim; Arman Zaharil Mat Saad; Nik Soriani Yaacob; Abdul Rahim Hussein; Faraizah Abdul Karim; Ahmad Hazri Abdul Rashid; Zanariah Ujang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

Authors:  Veronica H Flood; Pamela A Christopherson; Joan Cox Gill; Kenneth D Friedman; Sandra L Haberichter; Daniel B Bellissimo; Rupa A Udani; Mahua Dasgupta; Raymond G Hoffmann; Margaret V Ragni; Amy D Shapiro; Jeanne M Lusher; Steven R Lentz; Thomas C Abshire; Cindy Leissinger; W Keith Hoots; Marilyn J Manco-Johnson; Ralph A Gruppo; Lisa N Boggio; Kate T Montgomery; Anne C Goodeve; Paula D James; David Lillicrap; Ian R Peake; Robert R Montgomery
Journal:  Blood       Date:  2016-02-09       Impact factor: 22.113

3.  Markers of vascular perturbation correlate with airway structural change in asthma.

Authors:  Mats W Johansson; Stanley J Kruger; Mark L Schiebler; Michael D Evans; Ronald L Sorkness; Loren C Denlinger; William W Busse; Nizar N Jarjour; Robert R Montgomery; Deane F Mosher; Sean B Fain
Journal:  Am J Respir Crit Care Med       Date:  2013-07-15       Impact factor: 21.405

Review 4.  Advances in the diagnosis and treatment of Von Willebrand disease.

Authors:  Ruchika Sharma; Veronica H Flood
Journal:  Blood       Date:  2017-11-30       Impact factor: 22.113

5.  Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene.

Authors:  Heidi L Lemmerhirt; Jordan A Shavit; Gallia G Levy; Suzanne M Cole; Jeffrey C Long; David Ginsburg
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

Review 6.  Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency.

Authors:  P James; O Salomon; D Mikovic; F Peyvandi
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

7.  The role of genetics in the pathogenesis and diagnosis of type 1 Von Willebrand disease.

Authors:  Veronica H Flood; Jessica Garcia; Sandra L Haberichter
Journal:  Curr Opin Hematol       Date:  2019-09       Impact factor: 3.284

Review 8.  The evolution and value of bleeding assessment tools.

Authors:  Natalia Rydz; Paula D James
Journal:  J Thromb Haemost       Date:  2012-11       Impact factor: 5.824

Review 9.  von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.

Authors:  Paula D James; David Lillicrap
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

10.  No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.

Authors:  Veronica H Flood; Kenneth D Friedman; Joan Cox Gill; Sandra L Haberichter; Pamela A Christopherson; Brian R Branchford; Raymond G Hoffmann; Thomas C Abshire; Amy L Dunn; Jorge A Di Paola; W Keith Hoots; Deborah L Brown; Cindy Leissinger; Jeanne M Lusher; Margaret V Ragni; Amy D Shapiro; Robert R Montgomery
Journal:  Blood       Date:  2013-03-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.